December 17, 2007

Chandra Lovejoy Joins Endocyte as Director of Regulatory Affairs

Lovejoy comes to Endocyte from Genentech Inc., South San Francisco, Calif., where she was most recently a manager of regulatory affairs. In this role, she provided regulatory leadership to support the development of key oncology programs, including strategy for registration trials, formal FDA meetings and regulatory submissions, among other responsibilities.

"Lovejoy's extensive experience in oncology product development will be an important asset to Endocyte," said Ron Ellis, president and CEO of Endocyte. "Her work with the FDA in the area of oncology brings us the regulatory leadership we need as we progress through our clinical programs."

About Endocyte Inc.

Endocyte Inc., located at the Purdue Research Park in West Lafayette, Ind., uses an advanced targeting technology that makes it possible to develop custom guidance systems for drugs. The technology makes drugs more effective by targeting them directly to receptors found on diseased cells. With improved targeting, Endocyte can develop products using proven powerful drugs that are currently not widely used because of dose limiting toxicities.  Drugs can be dosed at higher levels and on uninterrupted schedules for maximum efficacy with reduced side effects. 

Endocyte is currently testing four agents in clinical trials: EC20, a targeted diagnostic imaging agent used to identify patients likely to respond to the therapy; EC145, a targeted chemotherapeutic agent in phase 2 studies for patients with advanced ovarian and non-small cell lung cancers; EC17, a targeted immunotherapy in a phase 2 study of advanced kidney cancer; and EC0225, a chemotherapeutic agent targeting two drugs currently in a phase 1 clinical study. In addition, Endocyte has established a collaborative development program with Bristol-Myers Squibb.

For further information, visit https://www.endocyte.com.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve significant risks and uncertainties that may cause results to differ materially from those set forth in the statements. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

To the Purdue Research Park, https://www.purdueresearchpark.com

Contact: Vickey Buskirk, media relations, Endocyte Inc., (765) 463-7175 ext. 1117, vbuskirk@endocyte.com